Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TCT 2015 ROUND UP: More Transcatheter Aortic Valve Results, Super-Thin Strut Stents, and Percutaneous Heart Pumps

This article was originally published in Clinica

Executive Summary

Clinical trials of transcatheter aortic valve technologies once again dominated news coming out of the Transcatheter Cardiovascular Therapeutics conference, held this year in San Francisco, Oct. 10-15. But the meeting also featured new coronary stent technologies and new information on percuataneous heart pumps to support patients during difficult interventions.

You may also be interested in...



Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH

Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.

News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared

This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.

Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS

Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel